BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chorostowska-Wynimko J, Barrecheguren M, Ferrarotti I, Greulich T, Sandhaus RA, Campos M. New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency. Int J Chron Obstruct Pulmon Dis 2020;15:345-55. [PMID: 32103933 DOI: 10.2147/COPD.S234646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Miravitlles M, Herepath M, Priyendu A, Sharma S, Vilchez T, Vit O, Haensel M, Lepage V, Gens H, Greulich T. Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews. Eur Respir Rev 2022;31:210262. [PMID: 35321931 DOI: 10.1183/16000617.0262-2021] [Reference Citation Analysis]
2 Herth FJF, Sandhaus RA, Turner AM, Sucena M, Welte T, Greulich T. Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic. Int J Chron Obstruct Pulmon Dis 2021;16:2983-96. [PMID: 34754184 DOI: 10.2147/COPD.S325211] [Reference Citation Analysis]
3 Barjaktarevic I, Campos M. Management of lung disease in alpha-1 antitrypsin deficiency: what we do and what we do not know. Ther Adv Chronic Dis 2021;12_suppl:20406223211010172. [PMID: 34408831 DOI: 10.1177/20406223211010172] [Reference Citation Analysis]
4 Burkes RM, Panos RJ. Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease. J Exp Pharmacol 2020;12:589-602. [PMID: 33364854 DOI: 10.2147/JEP.S259328] [Reference Citation Analysis]